Our support to authors:
- Submit your manuscript without worries: we are flexible at first submission, all formats accepted ! no other documents required. You can submit one pdf file with all text, tables and figures.
- Was your manuscript previously reviewed ? Send us the comments of the previous reviewers and your explanation on how you have revised the manuscript based on these comments. We will take it into account and speed up the review process of your manuscript.
- We typically do only 2 rounds of revision – no endless discussions with the reviewers.
- Do you have very important results ? Request a fast-track review and get a decision on your manuscript within 7 days.
- All accepted articles are published in full open access. No login required to read the full text or pdf versions of all articles. No additional fees for open access, it is included.
- Haematologica is the number 1 open access journal in the hematology field with a current impact factor of 9.090.
Submit to Haematologica today !
A. General information
Haematologica publishes articles in the broad field of hematology, reporting on novel findings in basic, clinical and translational research.
The scope of the journal is to report novel research results that have an important impact on our understanding of normal hematology or the development of hematological diseases, or are likely to bring important changes to the diagnosis or treatment of hematological diseases.
All articles are evaluated based on an international peer review process. Less than 20% of submitted articles can be accepted. Articles will be selected based on novelty, importance for the field and experimental quality.
Authors should fully disclose and provide all information on sequences, chemical structures, recombinant proteins, cell lines, datasets, etc.
We are proud to offer an easy submission system and a rapid and fair peer review with only 19 days as average time to first decision. We aim to provide a clear decision on the acceptance or rejection of a manuscript, with maximum 2 revisions, in order not to delay publication of research results. Requests for fast-track review are possible (see further down).
Haematologica is an Open Access Journal, as the Ferrata Storti Foundation and the European Hematology Association believe that works reporting the results of scientific research should be openly accessible and freely usable by the entire scientific community.
The current impact factor of Haematologica is 9.090 (JCR 2016 impact factor). Haematologica ranks number 5 of 70 hematology journals.
Follow us on:
- the web: www.haematologica.org
- our app: download the app from the App Store or Google Play
- Facebook: www.facebook.com/haematologica
Fast-track review request
Manuscripts (original articles) that report extraordinary results that warrant rapid publication can be selected for fast-track review. Articles selected for fast-track review will receive an initial decision on the manuscript within 1 week.
We can only select a few articles for fast track, as this requires extra efforts of our reviewers and editors. These manuscripts should be of very high interest and report highly novel work, and will be selected by the editors. Note that also our regular review process is providing a decision within 19 days on average.
Authors can request fast-track review by e-mail: please send the manuscript as pdf file with an accompanying explanation why rapid review should be considered to: fast-track@haematologica.org
Manuscript submission
Manuscripts should be submitted through the online manuscript processing system: http://submit-haematol.highwire.org.
Attention: The author names and affiliations inserted in the online submission system will be those which will be published in PubMed as prepublication. The Haematologica Journal staff is therefore not responsible for eventual inaccuracies or mistakes in the affiliations inserted during the submission process.
Please, note: the affiliations that will appear in PubMed after the final publication of the paper will be those ones indicated by the authors during the proofreading and they will replace the ones appeared as prepublication
At initial submission, these files will be requested:
- one pdf file with the text, tables, and figures (please make sure the file size is below 5 Mb)
- one pdf file with all supplemental data
- Information on AUTHOR CONTRIBUTION and DISCLOSURES should be provided during online submission.
- We are very flexible on the format of the first submission - we believe that the data is important, not the format.
At submission of a revised manuscript, these files will be requested:
- one word document with text and tables (indicate in color the changes that were made compared to the first submission)
- single high quality files for each figure (jpg is preferred)
- one pdf file with all supplemental data
- download the checklist for the submission of a revised article or the submission of a revised letter
- at revision, we request that authors strictly follow our guidelines to ensure fast publication.
Submission fees
A nonrefundable fee of 50 Euro (including VAT) is due on submission of original articles. There is no submission fee for letters, case reports, comments, editorials, guideline articles and review articles. The publication fee covers the cost of the manuscript processing through the journal's online submission system, and is not refundable once the manuscript has been submitted. This is not a review or publication fee, and the payment of the submission fee is in no way related to the outcome of the in-house or external peer-review process.
Review process
All manuscripts submitted to Haematologica are critically assessed by external and inhouse experts in accordance with the principles of Peer Review (http://www.icmje.org/ethical_3peer.html), which is fundamental to the scientific publication process and the dissemination of sound science. Each paper is first evaluated by one or more editors, who will assess the overall quality and novelty of the work and the article's appropriateness for the scope of Haematologica. Articles that are not found to be relevant for Haematologica will not be send out for external review and will be returned to the authors. The remaining articles are reviewed by external referees (second step of classical peer-review). We aim to provide feedback to the authors in less than 4 weeks after submission.
Publications charges
Once an article is accepted and in press, authors are required to pay publication charges. These fees cover the cost for Open Access and for publication of the article in print, online and through various other applications. All Haematologica articles are also uploaded to PubMed Central as a digital preservation service to our authors.
Fees (2018):
- Articles: For all the papers the publication charge is € 1600 (plus VAT when needed).
- Letters/Case reports: a publication charge of € 300 (plus VAT when needed) is due before publication.
- Editorials, Review Articles, Guideline Articles, Comments: Free of charge
These fees include all publication charges, including page charges, costs for color images, open access, and costs for online supplements. No other costs will be charged.
Copyright
Authors will grant copyright of their article to the Ferrata Storti Foundation. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties. Please contact the office for requests: office@haematologica.org
Clinical trials
Obligation to Register Clinical Trials
We believe that it is important to foster a comprehensive, publicly available database of clinical trials. We therefore request, as a condition of consideration for publication, the registration of all clinical trials in a public trials registry. The ICMJE provides specific guidelines on this topic (http://www.icmje.org/publishing_10register.html). The ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, and the like.
Haematologica does not advocate one particular registry, but follows the ICMJE recommendations. Because it is critical that trial registries are independent of for-profit interests, the ICMJE policy requires registration in a WHO primary registry rather than solely in an associate registry, since for-profit entities manage some associate registries. The details of the ICMJE policy are published online (http://www.icmje.org/faq_clinical.html).
Randomized Clinical Trials
When submitting manuscripts that report on randomized clinical trials, authors should provide - as a separate document - a flow diagram in CONSORT format and all of the information required by the CONSORT checklist (http://www.consort-statement.org). When submitting meta-analyses of randomized controlled trials, authors should provide both the QUOROM statement checklist and the QUOROM statement flow diagram http://www.consort-statement.org/index.aspx?o=1065). Documented review and approval from a formally constituted review board (Institutional Review Board - IRB - or Ethics committee) is required for all studies (prospective or retrospective) involving people, medical records, and human tissues. Haematologica requires that the authors provide this information on the manuscript's website, and also that they report it explicitly under 'Methods'.
Ethical considerations
Protection of human individuals in research
When reporting experiments on human individuals, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.
Patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication.
Protection of animals in research
When performing experiments on animals or animal tissues, authors should seek approval by an institutional ethics committee and should strictly follow the institutional and national guide for the care and use of laboratory animals. At time of manuscript submission, authors should provide information on the study approval by an institutional ethical committee. We can only consider manuscripts reporting on studies on animals or animal tissues if ethical committee approval of the study can be documented.
B. Manuscript preparation
1. Manuscript style
Manuscripts should be prepared according to the Uniform Requirements established by the International Committee of Medical Journal Editors (ICMJE): http://www.icmje.org/manuscript_1prepare.html
Manuscripts should be prepared using American English spelling, and should be submitted as Word files. Submit one manuscript file with the main text, figure legends and tables. Save your file in .doc format (not as .docx file).
Scientific nomenclatur should be used without Saxon Genitive (for example: use 'Hodgkin Lymphoma' and not 'Hodgkin's Lymphoma'). Saxon Genitive should be maintained in references.
Abbreviations or acronyms should only be used when necessary (do not use abbreviations of words that are only used once or twice in the entire text), and should be explained at their first use. Abbreviations should not be used in the title and also not in the abstract (gene symbols are allowed, common abbreviations such as 'PCR' are allowed - do not use 'AML' but use 'acute myeloid leukemia' in title and abstract).
Units and measurements: The SI system should be used for all scientific units. Please refer to http://www.bloodindex.com/normal_laboratory_values.php for hematological measures. Authors can also refer to http://www.unc.edu/~rowlett/units/scales/clinical_data.html for conversions from conventional units to SI units. Please adopt standardized abbreviations and define full forms in footnotes, e.g. “NA” (not applicable) ; “ND” (not determined).
The use of commercial names of drugs should be avoided. Drugs should only be referred to under their generic names unless different products are being compared. (for example: Use deferiprone, not Ferriprox)
Use the official gene symbols when referring to genes, transcripts, proteins. (for example: Use ABL1, not ABL or c-ABL ; use MYC, not c-Myc). Use this database as a reference: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene. Human Genes' names have to be indicated in Italic and capital, Human Proteins' names only in capital letter. Mouse and Rat Genes' names have to be indicated in italic, with only the first letter in capital and the remaining letters in lowercase (Shh). Mouse and Rat Proteins' names have to be indicated only in capital letter (SHH). Zebrafish and Frog (xenopus sp.) Genes' names have to be indicated in italic and all in lowercase (shh). Zebrafish and Frog (xenopus sp.) Proteins' names must have the first letter in capital and the remaining letters in lowercase.
References: Please follow the recommendations of ICMJE for the style of the references available at http://www.nlm.nih.gov/bsd/uniform_requirements.html. An Endnote style is available for download: Haematologica Endnote style (updated in 2015).
Image size and layout: Image layout should be simple, clear and precise. In order to promote good management of the space, images must take up the least space possible without compromising clarity. Figures can be either one column width (8 cm) or 2 column widths (16 cm). If the figure contains different panels their content should be identified (use capital letters to identify each panel) and described in the order in which they are presented. Please ensure that a description is provided for all parts of the figure. Please ensure that different parts of the image are shown in proportion to each other, e.g. axis scales and labels, internal descriptive text. Lines should be black (not grey) and sufficiently thick. Data which has no graphic significance to any part of the figure content and form should be presented as a separate table.
Figure quality: When a revised version of a manuscript is submitted, high quality figures will be required and will be asked to the authors. High quality figures should be submitted in jpg or tiff format. Note that we can not accept figures as presentation slides (Microsoft Powerpoint, Apple Keynote, or similar) as these can not be printed in high quality. The resolution of figures should be sufficiently high to allow clear sharp printing. The best way to determine if a figure is of sufficient quality is to print it in its final size: if all lines, letters, images are sharp and clear (not blurry or unfocused) and sufficiently large to read, then the figure is most likely fine. It is not possible to increase the quality of low quality images : be sure to capture high quality images at all times during experimental procedures. When making figures in adobe illustrator or similar software, export your figures as 300 dpi or 600 dpi jpg files (for text 600 dpi is likely to be the best option).
We can not accept low quality figures. A manuscript can not be accepted if the authors fail to provide high quality figures.
Reproductions and adaptations: The author must obtain written permission for the reproduction and adaptation of material that has already been published. Permission should be obtained from the copyright holder or publisher. Before a manuscript goes into print, Haematologica will need to receive a copy of the written permission. All material presented from other sources should be identified and should be accompanied by a specific reference in the legend confirming that permission for its use had been obtained, for example: “Adapted from Berger et al. Leukemia 2003, 17, 1820-1826; with permission.”
We are flexible at initial submission, but at submission of a revised manuscript these guidelines need to be followed carefully:
Download the checklist for the submission of a revised article or the submission of a revised letter.
2. Types of manuscripts
Articles are the main type of manuscripts, reporting both clinical and experimental hematology research studies that are of excellent quality and report novel findings that are of high importance for the field. These articles are to be divided into sections under the following subheadings: Abstract, Introduction, Methods, Results, Discussion, References. Results and Discussion can be combined in one section if appropriate.
- The abstract should be a summary of the work in maximum 250 words. State clearly the rationale for the study, how the study was performed, the most important results obtained, and the conclusions that can be drawn from this study. Articles reporting clinical trials should provide the trial registration number at the end of the abstract.
- The main text (introduction, methods, results, discussion) can be maximum 4000 words.
- The methods section in the article should be a brief summary of the most important methods (maximum 500 words), and is placed after the introduction. Describe basic material (patient samples, cell lines, specific methods, special reagents, ...).
If more space is needed for the methods, this can be provided in the online supplement that will be published with the online version of the article. There is no restriction to the length of the online methods section, but avoid making this part unnecessary long.
- References should be given in the correct style (see the latest issue of Haematologica for an example), with a maximum of 50 references.
- Figures and tables: Original articles can contain 8 display items (figures and/or tables). Authors are requested to provide the tables as text files in the manuscript file (word file). Tables should only contain data that is essential for the manuscript. Large additional tables (for example with patient characteristics, primer sequences, etc.) should be placed in the supplement. Authors are requested to provide the figures as high resolution images (jpg or tiff – power point figures are not accepted) in the final size in which they will be published, taking the relative size of all the graphs into account, as well as the size of letters and symbols in the graphs.
- All supplementary material should be prepared and submitted as one single pdf file. This file will also be reviewed by the reviewers. In case of acceptance of the manuscript, this supplemental pdf file will be published as provided by the authors (this file will not be edited by the journal office, it is the reponsibility of the authors to ensure the supplement is complete and correct).
Review articles are invited articles, direct submission without invitation is not possible. Review articles are maximum 5000 words long (excluding figure legends and references) and do not have a specific structure. The articles should contain an abstract (short summary of the topic without specific structure) of maximum 250 words, may contain several display items in color, and have a reference list of maximum 100 references. These articles should not simply go over or summarize general information which is already known, but also discuss the importance of the data and provide a clear view on how these insights have transformed or will transform the hematology field. Authors of review articles are encouraged to include 4 to 6 figures. Authors should only provide a draft of the figures (all formats acceptable), as the final high quality figures for review articles will be generated by Somersault1824 (www.somersault1824.com).
Guideline articles should consist of meta-analyses and/or guidelines carried out and prepared by an international group of experts. These articles are up to 5000 words long (excluding figure legends and references) and do not have a specific structure. The articles should contain an unstructured abstract (short summary/ introduction) of maximum 200 words, may contain several display items in color, and have a reference list of maximum 100 references.
Editorials are commentaries or opinions on specific articles or on general concepts in hematology practice or research. These articles are usually invited articles, but proposals are welcome and should be addressed to the editorial office (office@haematologica.org). These articles have a free structure (no abstract, no specific subheadings), contain about 1,500 words (excluding references), up to 20 references and may contain two display items (figures and/or tables). Haematologica has a wide international readership both in the field of hematology and in other sectors of the medical profession. Its aim is to reach also those without specialized knowledge. Authors are asked to use simple, straightforward language to promote the understanding by all readers.
Letters to the Editor: We encourage submission of important new findings that fit into the format of a letter. Start the letter with a paragraph summarizing the rationale for the study and the major conclusions. Letters have no abstract, no headings, and a maximum of 1500 words in the text (excluding title, authors, affiliations, figures legends or references), a maximum of 3 tables and/or figures, and only 15 essential references. Letters will appear in the online version of the journal, will appear in the table of contents, and are indexed in pubmed.
Case Reports & Case Series: Detailed reports of special cases that contribute to a better mechanistic understanding of hematological diseases or to patient care will be considered for publication under 'Case Reports & Case Series'. These reports need to be conclusive and will need to describe various data (molecular data, biology data, etc.) in addition to the description of the clinical data. Only few case reports can be published and a strict selection is in place. Case Reports have no abstract, no headings, and a maximum of 1500 words in the text (excluding title, authors, affiliations, figure legends or references), a maximum of 3 tables and/or figures, and only 15 essential references. Case Reports will appear in the online version of the journal, will appear in the table of contents, and are indexed in pubmed.
Comments are the format to discuss a recently published article in Haematologica, or to discuss cutting edge ideas or developments in the broad field of hematology. Comments follow the same structure as Letters, but can not contain new data. Comments have no abstract, a maximum of 1000 words in the text (excluding title, affiliations, figures legends or references), and only 10 essential references. Please start the comment with a paragraph summarizing the rationale for the comment, citing the article or articles that form the basis for the comment. Comments will appear in the online version of the journal, will appear in the table of contents, and are indexed in pubmed.
Conflict of interest note:
Conflict of interest regarding papers that do not report original research (primary data). As detailed under Policies and Practices (http://www.haematologica.org/misc/policies.dtl) authors must disclose all relationships that could be viewed as potential conflicts of interest both in the online manuscript submission system and in the manuscript. These disclosures are expected to help readers in establishing whether the reported relationships may influence the authors’ judgment. Haematologica believes that this procedure is appropriate with respect to papers reporting original research (original articles, brief reports and research letters) as primary data speak for themselves. This procedure may be insufficient with respect to papers that do not report primary data, such as editorials, perspective articles, commentaries, review articles, guidelines, consensus papers and position papers. As stated by Kassirer & Angell [Kassirer JP, Angell M. Financial conflicts of interest in biomedical research. N Engl J Med. 1993 Aug 19;329(8):570-1. PubMed PMID: 8204121] “unlike reports of original research, these articles represent the judgment of their authors, based on their evaluation of the literature. What studies they select to discuss and their analysis of them are necessarily subjective. Bias may be extremely difficult to detect because these articles contain no primary data to speak for themselves.” Nonetheless, disclosing relationships that could be viewed as potential conflicts of interest may be acceptable in many of these papers. Haematologica, however, no longer considers for publication papers not reporting primary data - such as those listed above - whose preparation has been promoted, sponsored or supported in any way by a company whose product is discussed in the paper. In fact, the clear conflict of interest is very likely to influence judgment in these cases, and there are no primary data that can speak for themselves. This point is detailed in the online manuscript processing system; if doubts exist about this issue, the authors are invited to contact the editorial office (office@haematologica.org) before proceeding with submission.
3. Manuscript structure
3.1. Title Page
Information provided on the title page should correspond exactly with the information provided in the online system.
The title should consist of a phrase or a sentence; question forms should be avoided. Capitalize the first letter of the sentence only, and do not use abbreviations. Study group names may be presented in the title, however, all members’ names should be listed in an appendix and presented at the end of the main text; Add for example: A complete list of the members of the European Prospective Investigation into Cancer and Nutrition Group appears in a supplement. Acronyms such as EBMT, GOELAMS, GEIL, are acceptable. Commercial names of drugs should be avoided (use only the generic names), unless different products are being compared.
Names of authors should be presented as full first name, initial of middle name (if applicable) and full last name. Use a comma between each author, use “and” before the final author. Number authors’ affiliation in superscript. Do not include professional titles or abbreviations of qualifications or positions held.
A GROUP OF AUTHORS (CONTRIBUTORS) CREDITED UNDER ONE NAME, EITHER AS A COLLABORATION IN THE STRICTEST SENSE, OR WHEN AN ORGANIZATION, INSTITUTION, OR CORPORATION IS THE AUTHOR SHOULD BE INDICATED AS COLLABORATIVE GROUPS.
Authors’ affiliations should be provided on a new line immediately after the authors’ names. Every affiliation on a new line. Provide only the city and country (acronym for the USA countries) of each institute, not full address, the postal code is not needed.
Statement of equal authors’ contribution: In cases in which authors share equal responsibility for the study, a statement of equal contribution can be stated here. Use authors’ initials rather than full names, e.g. “GGH and FS contributed equally to this work.”
Running heads: please provide a shortened title as running head of maximum 50 characters. The use of acronyms and abbreviations is permitted.
Contact information for correspondence should confirm the name and e-mail address of the corresponding author or authors.
Word count: Provide a word count for the abstract and for the main text (= introduction + methods + results + discussion). Indicate how many tables and figures are present in the manuscript. Indicate how many supplemental files are associated with the manuscript (we request 1 supplemental pdf file ; only in specific circumstances we can accept more than 1 supplemental file).
Trial registration: Confirmation and details of trial registration should be given on the first page; please use the following form: “clinicaltrials.gov identifier: NCT00123456.”
Acknowledgments should refer to secretarial and editorial assistance, technical and intellectual input and advice, funding, fellowships and grants. The form to be used is “The authors would like to thank...”
3.2. Abstract
Summary of the work, word limit is dependent on the type of article.
Letters, Case reports and editorials do not have an abstract.
3.3.Main text
Word limit is dependent on the type of article.
Products that are commercially available should be clearly described with specific information, non-commercial products should be completely described in the manuscript or in the supplement. Sequences, chemical structures, datasets, etc. should be fully disclosed and made available to other researchers.
Tables and Figures: The presentation of Tables and Figures should always follow the same order in which they are presented in the main text. All references to Tables and Figures should be presented in brackets and should only specify “Table” or “Figure” and the relevant identification number.
When reference is made to more than one Table or more than one Figure, please separate the identification numbers with a hyphen and use “and” to present Tables or Figures that are not consecutive.
Please pay particular attention to spacing (for example: Figures 1-2; Tables 1 and 3; Figures 2-4 and 6; Tables 2, 4 and 6). References referring to Figure panels and subpanels should be presented by adding a capital letter in alphabetic order immediately after the identification number (for example: Figure 1A, Figure 1B). When reference is made to more than one Figure panel or subpanel, please separate the capital letters with a hyphen and use a comma followed by a space to separate capital letters that are not consecutive (for example: Figure 2 B-C ; Figure 3 B, D).
3.4. References
We use a new style since March 2015. Please see the latest issue of Haematologica for an example.
> You can download the reference style to be used by Endnote here:
In the main text, refer to published litterature by using a number, for example:
Melick and colleagues previously reported IDH1 mutations in AML.5
Several groups previously reported the presence of IDH1 mutations in AML.5-9
Two studies previously reported IDH1 mutations in AML.5,6
To generate the reference list, follow these new guidelines:
- For references with 6 or less than 6 authors, list all authors:
Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The serine protease matripase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Met. 2008;8(6):502-511.
- For references with more than 6 authors, list the first 3 authors followed by "et al."
Rose ME, Huerbin MB, Melick J, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002;935(1-2):40-46.
- For articles published ahead of print:
Those articles which have already been accepted for publication and which have been published ahead of print should follow the same reference format as a journal article, using the date on which the article was published ahead of print, e.g.
Bonci D, Musumeci M, Coppola V, Addario A, Conticello C, et al. Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity. Haematologica 2008 Oct 6. [Epub ahead of print]
- For personal communications:
Authors should specify the name of the person concerned, the affiliation, whether the reference concerns an oral or a written communication, and the date on which the communication was made. Written permission for the reference to be made must be obtained from the person concerned, a copy of which may be requested by the journal.
- For unpublished data:
Authors should provide the names of all persons responsible for the resource, a short description, and the relevant date.
3.5. Tables (tables should be placed after the references)
Provide tables in a simple format, without specific layout. The final layout will be given by journal staff at time the final manuscript pdf file is prepared. Tables should have a short clear title. Provide a legend to the table (if needed) directly below the table. Explain all abbreviations that are used in the table in the legend.
3.6. Figure legends (figure legends should be placed after the tables)
Figures should be numbered consecutively in the order in which they are presented in the main text, e.g. Figure 3. Give every figure a short clear title, followed by a brief description of figure content. Provide sufficient detail in the figure legend, but do not repeat what is discussed in the text.
3.7. Supplements
In addition to the main Word file, one additional pdf file can be submitted containing supplemental material. Please prepare one single pdf file containing all supplemental data (supplemental methods, supplemental data, supplemental figures, supplemental tables).
Additional files that can not be incorporated in a pdf file (such as video, large excel tables running over several pages, etc.) can be provided separately.
Please submit the manuscript with the tables and figure legends placed after the references.
Any specific questions can be addressed to: office@haematologica.org
follow us on Facebook: www.facebook.com/haematologica